pharmaphorum recently published an article written by our Founder and CEO Yin Ho and Associate Data Analyst Daniel Liden: "Sovaldi and the Politics of High Priced Drugs: Are We Asking the Right Questions?"
The article gives our perspective on an issue that has been getting a lot of attention these days, Gilead's Hepatitis C drug Sovaldi. There have been a variety of opinions about Sovaldi and the high price, but we thought it would be interesting to see how agencies around the world are evaluating its cost-effectiveness, and how that compares to recent questions from members of the United States Congress.
When it comes to high priced drugs, are we asking the right questions?
Click here to read the full article.